SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-010236
Filing Date
2022-06-23
Accepted
2022-06-23 17:30:32
Documents
12
Period of Report
2022-06-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20220622x8k.htm   iXBRL 8-K 37662
  Complete submission text file 0001558370-22-010236.txt   161484

Data Files

Seq Description Document Type Size
2 EX-101.SCH sgtx-20220622.xsd EX-101.SCH 2993
3 EX-101.LAB sgtx-20220622_lab.xml EX-101.LAB 16585
4 EX-101.PRE sgtx-20220622_pre.xml EX-101.PRE 10459
6 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20220622x8k_htm.xml XML 5047
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 221036455
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences